Info on accelerated approval for BRUKINSA

Please be aware NCCN has recently updated their Oncology Guidelines for Mantel Cell Leukemia (MCL) based on the accelerated approval for BRUKINSA.

NCCN has provided BRUKINSA (zanubrutinib) in R/R MCL with a Level 2A Preferred evidence listing, comparable to other BTKi in the class.

This is the link to the NCCN main website,

© 2021 FLASCO | Premium Website Design by The HDG